Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies

This viewpoint discusses potential problems with the US Food and Drug Administration’s emergency use authorization document allowing hydroxychloroquine and chloroquine for the treatment of coronavirus disease 2019 (COVID-19).

JAMA Internal Medicine